Product and Company News from the 7/22 News Brief

Product News

Biopharmaceutical company QLT announced that it has received final approval from the FDA to market Aczone (dapsone) Gel, for the topical treatment of acne vulgaris.

Company news

Allergan and Pharmacopeia have reached an agreement to research compounds for age-related macular degeneration (AMD). Allergan seeks to strengthen its ocular diseases franchise via possible future acquisitions of Pharmacopeia's novel compounds targeting angiogenesis.

AstraZeneca has agreed to pay up to $340m in cash and conditional milestone payments to Avanir, to license compounds for cardiovascular disease.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.